NCT01958619View on ClinicalTrials.gov

Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Malaria

Interventions

DRUG

1440mg PQP tablets

Piperaquine phosphate tablets (1440mg)

DRUG

960mg PQP tablets

Piperaquine phosphate tablets (960mg)

DRUG

800mg OZ439 + TPGS

OZ439 (800mg) + TPGS granules for oral suspension

DRUG

960mg PQP granules

Piperaquine phosphate granules for oral solution (960mg)

Trial Locations (1)

CR7 7YE

Richmond Pharmacology Ltd., Croydon

All Listed Sponsors

collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT01958619 - Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers | Biotech Hunter | Biotech Hunter